304 related articles for article (PubMed ID: 27366220)
1. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.
Kopylov U; Seidman E
Therap Adv Gastroenterol; 2016 Jul; 9(4):513-26. PubMed ID: 27366220
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.
Papamichael K; Vande Casteele N; Ferrante M; Gils A; Cheifetz AS
Inflamm Bowel Dis; 2017 Sep; 23(9):1510-1515. PubMed ID: 28816757
[TBL] [Abstract][Full Text] [Related]
3. Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East.
Nigam GB; Chatten K; Sharara A; Al-Taweel T; Alharbi O; Elamin H; Al Awadhi S; Annese V; Limdi JK
Therap Adv Gastroenterol; 2024; 17():17562848241230902. PubMed ID: 38406794
[TBL] [Abstract][Full Text] [Related]
4. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review.
Wang LF; Chen PR; He SK; Duan SH; Zhang Y
World J Gastroenterol; 2023 Aug; 29(29):4481-4498. PubMed ID: 37621757
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
Clark-Snustad KD; Singla A; Lee SD
Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
[TBL] [Abstract][Full Text] [Related]
6. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.
Papamichael K; Gils A; Rutgeerts P; Levesque BG; Vermeire S; Sandborn WJ; Vande Casteele N
Inflamm Bowel Dis; 2015 Jan; 21(1):182-97. PubMed ID: 25222660
[TBL] [Abstract][Full Text] [Related]
7. Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?
Gisbert JP; Chaparro M
Scand J Gastroenterol; 2015 Apr; 50(4):379-86. PubMed ID: 25636030
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease.
de Silva PS; Nguyen DD; Sauk J; Korzenik J; Yajnik V; Ananthakrishnan AN
Aliment Pharmacol Ther; 2012 Sep; 36(5):459-66. PubMed ID: 22784296
[TBL] [Abstract][Full Text] [Related]
9. Optimizing anti-TNF treatments in inflammatory bowel disease.
Ben-Horin S; Kopylov U; Chowers Y
Autoimmun Rev; 2014 Jan; 13(1):24-30. PubMed ID: 23792214
[TBL] [Abstract][Full Text] [Related]
10. Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Porcari S; Viola A; Orlando A; Privitera AC; Ferracane C; Cappello M; Vitello A; Siringo S; Inserra G; Magnano A; Mocciaro F; Di Mitri R; Belluardo N; Fidanza O; Garufi S; Magrì G; Bertolami C; Carroccio A; Macaluso FS; Renna S; Ventimiglia M; Alibrandi A; Cottone M; Fries W;
Drugs Aging; 2020 May; 37(5):383-392. PubMed ID: 32016824
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus.
Greuter T; Maillard MH; Juillerat P; Michetti P; Seibold F; Mottet C; Zahnd N; Sauter B; Schoepfer AM; Rogler G; Vavricka SR;
Digestion; 2020; 101(6):683-691. PubMed ID: 31461706
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases.
Felice C; Marzo M; Pugliese D; Papa A; Rapaccini GL; Guidi L; Armuzzi A
Expert Opin Biol Ther; 2015; 15(8):1107-17. PubMed ID: 25947043
[TBL] [Abstract][Full Text] [Related]
14. Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?
Anjie SI; Hulshoff MS; D'Haens G
Expert Opin Biol Ther; 2023 Apr; 23(4):341-351. PubMed ID: 37010030
[TBL] [Abstract][Full Text] [Related]
15. Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients.
Cha JM; Park DI; Park SH; Shin JE; Kim WS; Yang SK
J Korean Med Sci; 2017 Jan; 32(1):85-94. PubMed ID: 27914136
[TBL] [Abstract][Full Text] [Related]
16. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.
Ben-Horin S; Mazor Y; Yanai H; Ron Y; Kopylov U; Yavzori M; Picard O; Fudim E; Maor Y; Lahat A; Coscas D; Eliakim R; Dotan I; Chowers Y
Aliment Pharmacol Ther; 2012 Mar; 35(6):714-22. PubMed ID: 22288419
[TBL] [Abstract][Full Text] [Related]
17. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease.
Dubinsky MC; Mei L; Friedman M; Dhere T; Haritunians T; Hakonarson H; Kim C; Glessner J; Targan SR; McGovern DP; Taylor KD; Rotter JI
Inflamm Bowel Dis; 2010 Aug; 16(8):1357-66. PubMed ID: 20014019
[TBL] [Abstract][Full Text] [Related]
18. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
[TBL] [Abstract][Full Text] [Related]
19. TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease.
Altwegg R; Vincent T
Mediators Inflamm; 2014; 2014():172821. PubMed ID: 24757282
[TBL] [Abstract][Full Text] [Related]
20. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.
Pouillon L; Bossuyt P; Peyrin-Biroulet L
Expert Opin Biol Ther; 2016 Oct; 16(10):1277-90. PubMed ID: 27329436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
